Jeffrey S. Forsse, D. Buckley, Ahmed Ismaeel, Kathleen E. Adair, R.L.N Torres, Catherine Lowry, Anurag Dhillon, P. Koutakis
Introduction: Serum creatinine (sCr) is conventionally used to characterize the progressive decline in renal filtration (RF). Assessment of RF and renal health (RH) is traditionally believed to be agedependent. However, in the absence of cardiometabolic disease (CMD), this may not be the case. Objectives: The purpose of this study was to determine the magnitude of age as an influencing factor independent of CMD with novel markers of RH/RF in a single health assessment. Patients and Methods: Fifty-four participants (n = 27 men; n = 27 women; age 33.4 ± 12.5 years; BMI 26.5 ± 5.5; SBP 120 ± 10.4; DBP 77.7 ± 6.7; CHOL 174 ± 30) free of CMD were recruited to assess sCr, urine creatinine (uCr), cystatin C (CyC), and urine epidermal growth factor (uEGF) to calculate estimates of RH/F via uEGF/uCr ratio (uEGFR), eGFR - modification of diet in renal disease (MDRD), CKD-EPI, and sCr/CyC eGFR. Results: There were no significant differences between age groups (20s, 30s, 40s, 50s) in biomarkers and estimates of RH/RF, sCr (P=0.91), uEGF (P=0.46), CyC (P=0.13), CyC eGFR (P= 0.10), MDRD (P=0.12), CKD-EPI (P=0.80), and sCr/CyC eGFR (P=0.12). Post-hoc analysis revealed uEGFR was the only significantly different variable between 40s and 50s age groups (P= 0.02). Conclusion: Changes in RH/RF appear to be independent of age in the absence of CMD. Indicating RH/RF could potentially be maintained in adulthood and throughout the older adult years with the continued absence of CMD.
{"title":"In the absence of cardiometabolic diseases, is age an independent factor in assessing renal health and filtration? A pilot study","authors":"Jeffrey S. Forsse, D. Buckley, Ahmed Ismaeel, Kathleen E. Adair, R.L.N Torres, Catherine Lowry, Anurag Dhillon, P. Koutakis","doi":"10.34172/jnp.2022.17224","DOIUrl":"https://doi.org/10.34172/jnp.2022.17224","url":null,"abstract":"Introduction: Serum creatinine (sCr) is conventionally used to characterize the progressive decline in renal filtration (RF). Assessment of RF and renal health (RH) is traditionally believed to be agedependent. However, in the absence of cardiometabolic disease (CMD), this may not be the case. Objectives: The purpose of this study was to determine the magnitude of age as an influencing factor independent of CMD with novel markers of RH/RF in a single health assessment. Patients and Methods: Fifty-four participants (n = 27 men; n = 27 women; age 33.4 ± 12.5 years; BMI 26.5 ± 5.5; SBP 120 ± 10.4; DBP 77.7 ± 6.7; CHOL 174 ± 30) free of CMD were recruited to assess sCr, urine creatinine (uCr), cystatin C (CyC), and urine epidermal growth factor (uEGF) to calculate estimates of RH/F via uEGF/uCr ratio (uEGFR), eGFR - modification of diet in renal disease (MDRD), CKD-EPI, and sCr/CyC eGFR. Results: There were no significant differences between age groups (20s, 30s, 40s, 50s) in biomarkers and estimates of RH/RF, sCr (P=0.91), uEGF (P=0.46), CyC (P=0.13), CyC eGFR (P= 0.10), MDRD (P=0.12), CKD-EPI (P=0.80), and sCr/CyC eGFR (P=0.12). Post-hoc analysis revealed uEGFR was the only significantly different variable between 40s and 50s age groups (P= 0.02). Conclusion: Changes in RH/RF appear to be independent of age in the absence of CMD. Indicating RH/RF could potentially be maintained in adulthood and throughout the older adult years with the continued absence of CMD.","PeriodicalId":16515,"journal":{"name":"Journal of Nephropathology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42213372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Shafiee, Seyed Alireza Zomorodian, S. Owji, J. Roozbeh Shahroodi, M. Torabi Jahromi
Introduction: β-thalassemia intermedia reduces the body’s ability to produce adult hemoglobin and causes anemia. In contrast to β-thalassemia major, β-thalassemia intermedia patients do not require lifelong transfusion and are often independent of blood transfusion until young age. Moreover, chronic hypoxia and iron overload may cause tubular and glomerular dysfunction in patients with thalassemia. Case Presentation: We report a 21-year-old female with β-thalassemia intermedia (β-TI) presenting with generalized edema and proteinuria and showed membranoproliferative glomerulonephritis (MPGN) after renal biopsy. Conclusion: The possibility of occurrence of MPGN in patients with thalassemia should be considered. To our knowledge, it is the first case of thalassemia that was reported with MPGN and, more investigation is required to assess the association of thalassemia and MPGN.
{"title":"Membranoproliferative glomerulonephritis in β-thalassemia intermedia; a case report","authors":"M. Shafiee, Seyed Alireza Zomorodian, S. Owji, J. Roozbeh Shahroodi, M. Torabi Jahromi","doi":"10.34172/jnp.2022.17186","DOIUrl":"https://doi.org/10.34172/jnp.2022.17186","url":null,"abstract":"\u0000 Introduction: β-thalassemia intermedia reduces the body’s ability to produce adult hemoglobin and causes anemia. In contrast to β-thalassemia major, β-thalassemia intermedia patients do not require lifelong transfusion and are often independent of blood transfusion until young age. Moreover, chronic hypoxia and iron overload may cause tubular and glomerular dysfunction in patients with thalassemia. Case Presentation: We report a 21-year-old female with β-thalassemia intermedia (β-TI) presenting with generalized edema and proteinuria and showed membranoproliferative glomerulonephritis (MPGN) after renal biopsy. Conclusion: The possibility of occurrence of MPGN in patients with thalassemia should be considered. To our knowledge, it is the first case of thalassemia that was reported with MPGN and, more investigation is required to assess the association of thalassemia and MPGN.","PeriodicalId":16515,"journal":{"name":"Journal of Nephropathology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44093132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
R. Prabhu, B. Naik, M. Bhojaraja, I. Rao, S. Shenoy, S. Nagaraju, D. Rangaswamy
Introduction: Intradialytic hypertension (IDH) is associated with significant vascular and cardiac adverse outcomes. Objectives: This study was performed to know the prevalence and factors predicting IDH. Patients and Methods: A single-center cross-sectional observational study at a tertiary care hospital. After ethics committee approval and informed consent, all patients over 18 years on twice weekly hemodialysis were included, those on peritoneal dialysis and acute kidney injury excluded. Primary outcome was prevalence of IDH based on three definitions and secondary outcome was predictive factors. IDH was defined as ≥10 mm Hg surge in systolic blood pressure (SBP) between pre-and postdialysis in 4 of 6 successive sessions or >15 mm Hg rise in mean arterial pressure (MAP) between start and end of dialysis or symptomatic rise in blood pressure requiring intervention. SBP and MAP were measured on standardized monitors before, hourly and 30 minutes post dialysis. Results: Of 136 patients, prevalence of intra-dialytic hypertension was 78/136 (57%), 33/136 (24%), 15/136 (11%) based on systolic rise, rise in MAP and symptomatic rise in BP respectively. Among those with systolic rise, diabetes mellitus (P= 0.03), undernourishment (P=0.03), inter-dialytic weight gain >3 kg (P< 0.001) and dialysis vintage > 3 years (P< 0.001) were significantly associated with IDH. Conclusion: IDH prevalence varied from 11 to 57% with different definitions. Diabetes mellitus, under nutrition, inter-dialytic weight gain >3 kg and dialysis vintage >3 years predicted IDH.
{"title":"Intradialytic hypertension prevalence and predictive factors: A single centre study","authors":"R. Prabhu, B. Naik, M. Bhojaraja, I. Rao, S. Shenoy, S. Nagaraju, D. Rangaswamy","doi":"10.34172/jnp.2022.17206","DOIUrl":"https://doi.org/10.34172/jnp.2022.17206","url":null,"abstract":"\u0000 Introduction: Intradialytic hypertension (IDH) is associated with significant vascular and cardiac adverse outcomes. Objectives: This study was performed to know the prevalence and factors predicting IDH. Patients and Methods: A single-center cross-sectional observational study at a tertiary care hospital. After ethics committee approval and informed consent, all patients over 18 years on twice weekly hemodialysis were included, those on peritoneal dialysis and acute kidney injury excluded. Primary outcome was prevalence of IDH based on three definitions and secondary outcome was predictive factors. IDH was defined as ≥10 mm Hg surge in systolic blood pressure (SBP) between pre-and postdialysis in 4 of 6 successive sessions or >15 mm Hg rise in mean arterial pressure (MAP) between start and end of dialysis or symptomatic rise in blood pressure requiring intervention. SBP and MAP were measured on standardized monitors before, hourly and 30 minutes post dialysis. Results: Of 136 patients, prevalence of intra-dialytic hypertension was 78/136 (57%), 33/136 (24%), 15/136 (11%) based on systolic rise, rise in MAP and symptomatic rise in BP respectively. Among those with systolic rise, diabetes mellitus (P= 0.03), undernourishment (P=0.03), inter-dialytic weight gain >3 kg (P< 0.001) and dialysis vintage > 3 years (P< 0.001) were significantly associated with IDH. Conclusion: IDH prevalence varied from 11 to 57% with different definitions. Diabetes mellitus, under nutrition, inter-dialytic weight gain >3 kg and dialysis vintage >3 years predicted IDH.","PeriodicalId":16515,"journal":{"name":"Journal of Nephropathology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43365625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Choice of maintenance immunosuppressive therapy after renal transplantation is important for graft survival. However, complication may also occur. Venous thromboembolic event with the mTOR inhibitor (mTORi) everolimus is a rare but life-threatening complication. Here we describe a renal transplant recipient who developed pulmonary thromboembolism.
{"title":"Everolimus induced pulmonary thromboembolism after kidney transplantation; a case report","authors":"F. Saddadi, Mohammad Hassan Fallahkohan","doi":"10.34172/jnp.2022.11","DOIUrl":"https://doi.org/10.34172/jnp.2022.11","url":null,"abstract":"Choice of maintenance immunosuppressive therapy after renal transplantation is important for graft survival. However, complication may also occur. Venous thromboembolic event with the mTOR inhibitor (mTORi) everolimus is a rare but life-threatening complication. Here we describe a renal transplant recipient who developed pulmonary thromboembolism.","PeriodicalId":16515,"journal":{"name":"Journal of Nephropathology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43596385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Patients with kidney transplants are at greater risk of contracting COVID-19 because of long-term immunosuppression and may end up with severe disease with adverse outcome. The experiences of COVID-19 management in kidney transplant recipients are limited. This is a case of COVID-19 in a 45-year-old patient with a second renal transplant on triple immunosuppressive therapy who was successfully treated for COVID-19, septic shock, acute kidney injury and was discharged with a stable graft function. The patient presented with mild COVID-19 symptoms but later went into septic shock followed by acute kidney injury due to a secondary bacterial infection. The patient was successfully managed using antivirals, corticosteroids, reducing the dose of immunosuppressants initially, then discontinuing all the immunosuppressants in view of septic shock and finally reinstating the immunosuppression gradually on clinical improvement. This case report may serve as a reference for treating immunocompromised kidney transplant recipients having COVID-19. However, more data and experiences are needed for optimization of treatment of kidney transplant recipients with COVID-19.
{"title":"Coronavirus disease 2019 (COVID-19) in a kidney transplant recipient; case report","authors":"M. T. Kurian, S. Rabbani, A. C. Thomas, N. Javed","doi":"10.34172/jnp.2022.09","DOIUrl":"https://doi.org/10.34172/jnp.2022.09","url":null,"abstract":"Patients with kidney transplants are at greater risk of contracting COVID-19 because of long-term immunosuppression and may end up with severe disease with adverse outcome. The experiences of COVID-19 management in kidney transplant recipients are limited. This is a case of COVID-19 in a 45-year-old patient with a second renal transplant on triple immunosuppressive therapy who was successfully treated for COVID-19, septic shock, acute kidney injury and was discharged with a stable graft function. The patient presented with mild COVID-19 symptoms but later went into septic shock followed by acute kidney injury due to a secondary bacterial infection. The patient was successfully managed using antivirals, corticosteroids, reducing the dose of immunosuppressants initially, then discontinuing all the immunosuppressants in view of septic shock and finally reinstating the immunosuppression gradually on clinical improvement. This case report may serve as a reference for treating immunocompromised kidney transplant recipients having COVID-19. However, more data and experiences are needed for optimization of treatment of kidney transplant recipients with COVID-19.","PeriodicalId":16515,"journal":{"name":"Journal of Nephropathology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48800765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Kenarkoohi, M. Maleki, B. Ghiasi, Elham Bastani, I. Pakzad, M. Bonyadi, A. Abdoli, S. Falahi
Introduction: Hemodialysis (HD) patients are at increased risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Objectives: The aim of this study was to evaluate the prevalence and clinical symptoms of SARS-CoV-2 infection in HD patients. Patients and Methods: This is a single-center study conducted at HD center, in Ilam, Iran. The study was included 87 HD patients to be tested. SARS-CoV-2 infection was diagnosed with confirmed test by rRT-PCR (real-time reverse transcription polymerase chain reaction) assay. Results: Around 35.63% of HD patients were diagnosed as COVID-19 infection; most of them were male (74.4%). Dyspnea (58.1%) and cough (45.2%) were the most common symptoms among HD cases with SARS-CoV-2 infection. Diabetes (16.1%) and hypertension (19.4%) were the most coexisting medical illnesses. About 12.9% of patients needed ICU care. Additionally, 16.1% of our patients died, which all of them were male. Conclusion: This study showed a high prevalence of COVID-19 among our HD group, accompanied by mild symptoms. The HD population is probably among the most sensitive and high-risk groups for COVID-19 because of advanced age, comorbidities disease, low-immune function and frequent required visits, and patient overload in HD centers. Preventive measures should be taken in order to minimize the virus transmission in dialysis centers.
{"title":"Prevalence and clinical presentation of COVID-19 infection in hemodialysis patients","authors":"A. Kenarkoohi, M. Maleki, B. Ghiasi, Elham Bastani, I. Pakzad, M. Bonyadi, A. Abdoli, S. Falahi","doi":"10.34172/jnp.2022.07","DOIUrl":"https://doi.org/10.34172/jnp.2022.07","url":null,"abstract":"Introduction: Hemodialysis (HD) patients are at increased risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Objectives: The aim of this study was to evaluate the prevalence and clinical symptoms of SARS-CoV-2 infection in HD patients. Patients and Methods: This is a single-center study conducted at HD center, in Ilam, Iran. The study was included 87 HD patients to be tested. SARS-CoV-2 infection was diagnosed with confirmed test by rRT-PCR (real-time reverse transcription polymerase chain reaction) assay. Results: Around 35.63% of HD patients were diagnosed as COVID-19 infection; most of them were male (74.4%). Dyspnea (58.1%) and cough (45.2%) were the most common symptoms among HD cases with SARS-CoV-2 infection. Diabetes (16.1%) and hypertension (19.4%) were the most coexisting medical illnesses. About 12.9% of patients needed ICU care. Additionally, 16.1% of our patients died, which all of them were male. Conclusion: This study showed a high prevalence of COVID-19 among our HD group, accompanied by mild symptoms. The HD population is probably among the most sensitive and high-risk groups for COVID-19 because of advanced age, comorbidities disease, low-immune function and frequent required visits, and patient overload in HD centers. Preventive measures should be taken in order to minimize the virus transmission in dialysis centers.","PeriodicalId":16515,"journal":{"name":"Journal of Nephropathology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44374454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Mohammadi Kebar, S. Hoseininia, F. Pourfarzi, Elham Saeedi, S. Matin
Introduction: Hypomagnesaemia secondary to the use of proton-pump inhibitor (PPI) is associated with the reduction of blood pressure. Objectives: To determine the effect of PPI and ranitidine on the reduction of serum magnesium level and blood pressure in chronic hemodialysis patients with hypotension. Patients and Methods: In this double-blind randomized clinical trial, 44 hemodialysis patients who met the requirements entered the study. First, blood sample was taken from each of the patients and their serum magnesium level as well as their blood pressure was checked and recorded. Then, the patients in the intervention group received daily doses of ranitidine placebo (150 mg) and pantoprazole (40 mg) and those in the control group received daily doses of pantoprazole placebo (40 mg) and ranitidine (150 mg) for three months. After the intervention, blood samples were taken again in order to assess the patients’ serum magnesium level. The obtained data were fed into SPSS Software and analyzed. Results: The mean age of the patients was 60.14±12.98 years. Moreover, 63.6% of the total patients were female. In the group of patients who had received pantoprazole, diastolic pressure reduced significantly at the end of the study as compared to the beginning of the study. Moreover, in the patients receiving pantoprazole indicated a significant reduction of magnesium at the end of the study as compared to the beginning of the study. Conclusion: In this study, a significant relationship was also observed between the use of PPI and hypomagnesemia in hemodialysis patients. Trial registration: The trial protocol was approved in the Iranian Registry of Clinical Trials (identifier: IRCT20150808023559N19; https://en.irct.ir/trial/42478, ethical code# IR.ARUMS. REC.1398.295).
{"title":"The effect of proton-pump inhibitor and ranitidine on the reduction of serum magnesium level and blood pressure in chronic hemodialysis patients with hypotension; a doubleblind clinical trial","authors":"S. Mohammadi Kebar, S. Hoseininia, F. Pourfarzi, Elham Saeedi, S. Matin","doi":"10.34172/jnp.2022.17212","DOIUrl":"https://doi.org/10.34172/jnp.2022.17212","url":null,"abstract":"Introduction: Hypomagnesaemia secondary to the use of proton-pump inhibitor (PPI) is associated with the reduction of blood pressure. Objectives: To determine the effect of PPI and ranitidine on the reduction of serum magnesium level and blood pressure in chronic hemodialysis patients with hypotension. Patients and Methods: In this double-blind randomized clinical trial, 44 hemodialysis patients who met the requirements entered the study. First, blood sample was taken from each of the patients and their serum magnesium level as well as their blood pressure was checked and recorded. Then, the patients in the intervention group received daily doses of ranitidine placebo (150 mg) and pantoprazole (40 mg) and those in the control group received daily doses of pantoprazole placebo (40 mg) and ranitidine (150 mg) for three months. After the intervention, blood samples were taken again in order to assess the patients’ serum magnesium level. The obtained data were fed into SPSS Software and analyzed. Results: The mean age of the patients was 60.14±12.98 years. Moreover, 63.6% of the total patients were female. In the group of patients who had received pantoprazole, diastolic pressure reduced significantly at the end of the study as compared to the beginning of the study. Moreover, in the patients receiving pantoprazole indicated a significant reduction of magnesium at the end of the study as compared to the beginning of the study. Conclusion: In this study, a significant relationship was also observed between the use of PPI and hypomagnesemia in hemodialysis patients. Trial registration: The trial protocol was approved in the Iranian Registry of Clinical Trials (identifier: IRCT20150808023559N19; https://en.irct.ir/trial/42478, ethical code# IR.ARUMS. REC.1398.295).","PeriodicalId":16515,"journal":{"name":"Journal of Nephropathology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48539082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Thi Mai Dung Do, Phan Hai An Ha, Van Dong Le, Quang Thuan Huynh
Introduction: Immunological monitoring could indirectly measure the suppressive effects of the drugs and provide early guidance on necessary preventive interventions in transplant recipients. Objectives: Our goal was to determine whether mycophenolic acid (MPA) modulates peripheral blood lymphocyte T in kidney transplant recipients. Patients and Methods: We assessed T lymphocytes CD3, CD4 and CD8 in peripheral blood in 30 donors and 35 recipients one day before and 10 days after transplantation using Becton Dickinson’s direct immune fluorescent light. Results: Comparisons showed that the number of T lymphocytes CD3+, CD4+, CD8+ in peripheral blood of transplant recipients were lower than donors (TCD3 was 1690.31±503.45 versus 2280.73± 522.48; TCD4 was 549.51 ±211.72 cell/µL versus 766.37± 341.72 cell/µL and CD8 was 1134.37 ±431.07 cell/µL versus 1523.4± 349.23 cell/µL with P<0.001; P=0.001 and P= 0.0002 respectively). Additionally, post-transplantation lymphocytes TCD4 decreased in 10/35 of recipients and increased in 22/35 of recipients (P=0.036). Conclusion: The T lymphocytes CD3, CD4 and CD8 in peripheral blood should be monitored at multiple post-transplant times to make early predictions of transplant rejection during follow-up treatment.
{"title":"A survey on lymphocyte T CD3, CD4 and CD8 in peripheral blood of kidney transplant recipients using mycophenolic acid","authors":"Thi Mai Dung Do, Phan Hai An Ha, Van Dong Le, Quang Thuan Huynh","doi":"10.34172/JNP.2021.41","DOIUrl":"https://doi.org/10.34172/JNP.2021.41","url":null,"abstract":"\u0000 Introduction: Immunological monitoring could indirectly measure the suppressive effects of the drugs and provide early guidance on necessary preventive interventions in transplant recipients. Objectives: Our goal was to determine whether mycophenolic acid (MPA) modulates peripheral blood lymphocyte T in kidney transplant recipients. Patients and Methods: We assessed T lymphocytes CD3, CD4 and CD8 in peripheral blood in 30 donors and 35 recipients one day before and 10 days after transplantation using Becton Dickinson’s direct immune fluorescent light. Results: Comparisons showed that the number of T lymphocytes CD3+, CD4+, CD8+ in peripheral blood of transplant recipients were lower than donors (TCD3 was 1690.31±503.45 versus 2280.73± 522.48; TCD4 was 549.51 ±211.72 cell/µL versus 766.37± 341.72 cell/µL and CD8 was 1134.37 ±431.07 cell/µL versus 1523.4± 349.23 cell/µL with P<0.001; P=0.001 and P= 0.0002 respectively). Additionally, post-transplantation lymphocytes TCD4 decreased in 10/35 of recipients and increased in 22/35 of recipients (P=0.036). Conclusion: The T lymphocytes CD3, CD4 and CD8 in peripheral blood should be monitored at multiple post-transplant times to make early predictions of transplant rejection during follow-up treatment.","PeriodicalId":16515,"journal":{"name":"Journal of Nephropathology","volume":"84 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69815670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Kensaku Takahashi, S. Kitamura, Kazuhiko Fukushima, Yizhen Sang, Kenji Tsuji, J. Wada
Implication for health policy/practice/research/medical education: We examined how the image resolution affects the diagnosis not only artificial intelligence but also nephrologists in this study. The differences between human and artificial intelligence is specificity on diiferent resolution image diagnosis. The resolution of images might be important for not artificial intelligence but human on the point of specificity. Please cite this paper as: Takahashi K, Kitamura S, Fukushima K, Sang Y, Tsuji K, Wada J. The resolution of immunofluorescent pathological images affects diagnosis for not only artificial intelligence but also human. J Nephropathol. 2021;10(3):e26. DOI: 10.34172/jnp.2021.26. ARTICLE INFO
{"title":"The resolution of immunofluorescent pathological images affects diagnosis for not only artificial intelligence but also human","authors":"Kensaku Takahashi, S. Kitamura, Kazuhiko Fukushima, Yizhen Sang, Kenji Tsuji, J. Wada","doi":"10.34172/JNP.2021.26","DOIUrl":"https://doi.org/10.34172/JNP.2021.26","url":null,"abstract":"Implication for health policy/practice/research/medical education: We examined how the image resolution affects the diagnosis not only artificial intelligence but also nephrologists in this study. The differences between human and artificial intelligence is specificity on diiferent resolution image diagnosis. The resolution of images might be important for not artificial intelligence but human on the point of specificity. Please cite this paper as: Takahashi K, Kitamura S, Fukushima K, Sang Y, Tsuji K, Wada J. The resolution of immunofluorescent pathological images affects diagnosis for not only artificial intelligence but also human. J Nephropathol. 2021;10(3):e26. DOI: 10.34172/jnp.2021.26. ARTICLE INFO","PeriodicalId":16515,"journal":{"name":"Journal of Nephropathology","volume":"10 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43555928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：